Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Invion ( (AU:IVX) ) is now available.
Invion Limited has released a presentation to be used by its Executive Chair and CEO, Thian Chew, at investor meetings and seminars. The company is advancing its Photosoft™ technology, a next-generation Photodynamic Therapy (PDT) that offers a less invasive alternative to surgery for cancer treatment and has potential applications in combating antibiotic-resistant superbugs. This development positions Invion as a leader in innovative cancer and infectious disease treatments, potentially impacting its market presence and stakeholder interests.
More about Invion
Invion is a life-science company specializing in the research and development of Photosoft™ technology for treating cancers, atherosclerosis, and infectious diseases. The company holds exclusive licensing rights in various regions, including Australia, New Zealand, and parts of Asia and Oceania, and is listed on the ASX.
Average Trading Volume: 103,345
Technical Sentiment Signal: Sell
Current Market Cap: A$8.47M
For detailed information about IVX stock, go to TipRanks’ Stock Analysis page.